Analysts foresee more revenue Vertex Pharma

Tomorrow Vertex Pharma will publish its past quarter's results. For this year Vertex Pharma 's revenue will be around 2,33 billion USD. This is according to the average of the analysts' estimates. This is rather significant more than 2016's revenue of 1,7 billion USD.

Historical revenues and results Vertex Pharma plus estimates 2018

The analysts expect for 2018 a net profit of 477 million USD. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 1,89 USD. The price-earnings-ratio equals an extreme 88,43.

Analysts don't expect the company to pay a dividend.The average dividend yield of the biotech companies equals a limited 0,04 percent.

Latest estimates around 184 USD

Bank of America Merrill Lynch, Morgan Stanley and Deutsche Bank recently provided recommendations for the stock.

Vertex Pharma 's market capitalization is around 41,17 billion USD.

On Sunday the stock closed at 167,14 USD.

Historical stock prices Vertex Pharma

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.